Dosing Guide··8 min read

5-Amino-1MQ Dosage Chart: Oral + Injection Protocols

Oral runs 50-150mg/day. Community subcutaneous use reports 2.5-5mg/day — not interchangeable. Reconstitution units for 10, 20 and 50mg vials.

5-Amino-1MQ Dosing: 50-150mg/Day Oral Protocol

5-Amino-1MQ is a small-molecule NNMT inhibitor studied in preclinical obesity research and discussed in community sources in the context of fat loss, most often as an oral capsule (vials for subcutaneous use are also sold). It is not a peptide in the traditional sense but is commonly grouped with research peptides in the metabolic optimization space.

Research-context information only. 5-Amino-1MQ is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from preclinical animal research and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.

No published human clinical trials exist. All protocols are based on preclinical animal data and community experience. This is not medical advice.

The dosing table below covers only the subcutaneous vial form: the community protocol's 1 mg amount and the also-reported 2.5 mg and 5 mg amounts, at the dilutions shown in the reconstitution arithmetic section. Oral capsule amounts (50-150 mg/day) are reported separately in the Quick Reference and are not converted into syringe units.

5-Amino-1MQ Dosing Table

Match your vial size below — reconstitution and dose math update automatically.

Reconstitute: add 2 mL of bacteriostatic water to the 10 mg vial. Resulting concentration: 5 mg/mL.

Subcutaneous vial use: the community protocol (1 mg) and also-reported amounts. Oral capsule doses (50-150 mg/day) are not interchangeable and are not shown as syringe units.

1 mg20 units · 0.2 mL
AM SubQ, 5 days on / 2 off
Community protocol
2.5 mg50 units · 0.5 mL
Daily SubQ (or 2x/day split)
Also reported, tolerance phase
5 mg100 units · 1 mL
Daily SubQ
Also reported, day 3 onward

Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.

Reconstitute: add 1 mL of bacteriostatic water to the 10 mg vial. Resulting concentration: 10 mg/mL.

Subcutaneous vial use: the community protocol (1 mg) and also-reported amounts. Oral capsule doses (50-150 mg/day) are not interchangeable and are not shown as syringe units.

2.5 mg25 units · 0.25 mL
Daily SubQ (or 2x/day split)
Also reported, tolerance phase
5 mg50 units · 0.5 mL
Daily SubQ
Also reported, day 3 onward

Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.

Start the conversation

Quick Reference: Community Protocol

Parameter Community Protocol
Route Oral (capsule)
Community-reported starting dose 50 mg/day for 1-2 weeks
Commonly reported dose 100-150 mg/day
Timing Morning, with or without food
Frequency Once daily
Cycle 8-12 weeks on, 4-8 weeks off
Storage Room temperature, cool dry place

Community protocols describe a 50 mg/day starting phase lasting 1-2 weeks, escalating to 100-150 mg/day based on tolerance. Most reported protocols settle at 100 mg as the maintenance level. No reconstitution needed — oral capsule.

Dosage Per Day: What Protocols Report

Every documented community protocol quotes 5-Amino-1MQ per day, taken as a single morning dose: 50 mg per day during the 1-2 week assessment phase, 100-150 mg per day for the remainder of the cycle. Community protocols generally describe a single daily dose; sources attribute this to the compound's proposed sustained NNMT inhibition. Some subcutaneous reports use a twice-daily split (below).

Injection Dosage Per Day: What Community Sources Report

Oral capsules are the better-documented route, but vendors also sell 5-Amino-1MQ as lyophilised powder in 10 mg, 20 mg and 50 mg vials, and community discussion of subcutaneous use has followed. No human trial has established a dose for either route, and no study has established a conversion between them — the figures below are reported community practice, not clinical guidance.

Community protocol (subcutaneous):

Parameter Community protocol
Vial 10 mg
BAC water 2 mL (5 mg/mL)
Dose 1 mg (20 units on a U-100 insulin syringe)
Timing AM
Frequency 5 days on, 2 days off
Cycle 8 weeks on, 8 weeks off

Higher subcutaneous figures also circulate in other reports:

Reported phase Other reported amount Frequency
Days 1-2 (tolerance) 2.5 mg Once daily
Day 3 onward 5 mg Once daily
Split alternative 2.5 mg Twice daily

Those higher reports describe cycles of 8-12 weeks on, 4-6 weeks off. They run 2.5-5 times the community protocol's 1 mg, and no source documents why.

The oral and subcutaneous amounts are not interchangeable. Oral community protocols run 50-150 mg per day; the subcutaneous figures above (1-5 mg) are one to two orders of magnitude lower. That gap reflects an assumption about bypassing first-pass metabolism which has not been tested in humans for this compound, so neither number can be derived from the other.

The only subcutaneous dosing in the published research is animal work: 20 mg/kg in diet-induced-obese mice, up to three times daily (Neelakantan et al., 2018). Mouse milligram-per-kilogram figures do not scale linearly to humans and are not the source of the community amounts above.

Cycling Details

Community protocols report 8-12 weeks on / 4-8 weeks off; sources commonly cite the absence of long-term human safety data as the rationale. Community protocols describe gradual dose escalation rather than a loading phase.

Community protocols describe 50 mg daily in weeks 1-2 (assessing GI tolerance, energy changes, and side effects), then 100-150 mg daily in weeks 3-12 among users who report tolerating it. The off period is described as allowing assessment of sustained metabolic changes after discontinuation.

Community sources commonly describe morning dosing and consistent daily timing.

Bacteriostatic water vial — 0.9% benzyl alcohol multi-dose
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
Shop bac water made for peptides

Routes of Administration

Oral (the better-documented route): Capsule form, typically 50 mg capsules. Caco-2 cell assays showed excellent passive and active membrane transport with no detectable efflux (Neelakantan et al., 2018) — human oral bioavailability has not been formally established. Stable at room temperature. No reconstitution, syringes, or refrigeration needed.

5-Amino-1MQ Oral Administration

Subcutaneous: Sold as lyophilised powder in 10 mg, 20 mg and 50 mg vials, requiring bacteriostatic water, syringes and refrigeration after reconstitution. Unlike most compounds on this site, 5-Amino-1MQ is a small molecule with demonstrated membrane permeability, so the oral route is not the compromise it is for injectable peptides — which is why the oral protocol is the better-documented one. Use of the vial form rests on community practice rather than trial data.

Reconstitution arithmetic (illustrative, from vendor vial sizes)

Community reconstitution guides describe the following arithmetic for the vial sizes vendors list (concentration = vial mg ÷ BAC mL; units = dose mL × 100 on a U-100 syringe). The table shows what those amounts work out to, not a directed protocol:

Vial BAC water Concentration 1 mg dose 2.5 mg dose 5 mg dose
10 mg 2 mL (community protocol) 5 mg/mL 0.20 mL — 20 units 0.50 mL — 50 units 1.00 mL — 100 units
10 mg 1 mL 10 mg/mL 0.10 mL — 10 units 0.25 mL — 25 units 0.50 mL — 50 units
20 mg 2 mL 10 mg/mL 0.10 mL — 10 units 0.25 mL — 25 units 0.50 mL — 50 units
50 mg 3 mL 16.7 mg/mL 0.06 mL — 6 units 0.15 mL — 15 units 0.30 mL — 30 units

Illustrative only; none of these volumes has been tested or validated for this compound. At the community protocol's 1 mg, 5 days a week, a 10 mg vial covers two weeks; at the higher 2.5-5 mg daily figures a 50 mg vial covers roughly 10-20 days. Community discussions note that larger BAC volumes make small doses easier to measure, at the cost of a shorter in-use window once reconstituted.

Where These Numbers Come From

5-Amino-1MQ dosing is entirely community-derived, extrapolated from preclinical animal research. No human clinical trials have been conducted.

Key Preclinical Study (Neelakantan et al., 2018): Treatment in diet-induced obese mice produced progressive body weight loss, reduced white adipose tissue mass and adipocyte size, decreased total cholesterol, and no changes in food intake — effects were metabolic, not appetite-driven. The study used 20 mg/kg SC three times daily in mice.

NNMT as Target (Kraus et al., 2014): NNMT knockdown in white adipose tissue and liver protected against diet-induced obesity by increasing cellular energy expenditure. This established the mechanistic rationale for NNMT inhibition.

Combined Approaches (Neelakantan et al., 2022): NNMT inhibition with reduced-calorie diet produced dramatic adiposity reduction in DIO mice, normalizing metabolic parameters and establishing a distinct gut microbiome.

Community oral doses (50-150 mg daily) are described as extrapolated from mouse data, membrane-permeability findings, and several years of self-reported community experience.

Ready to buy? Compare verified vendors on our best 5-Amino-1MQ sources page. Vendors label these products for research use only, not for human consumption; nothing on this page is a direction for use.

Top 5-Amino-1MQ Vendors

Ranked by price, COA availability, and reputation

1
Nura PeptideCOA
10/10
$1.98/mg
2
Ascension PeptidesCOA
9.8/10
10mg$5.20/mg
3
LDAminosCOA
9.6/10
$1.92/mg

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Stacking Protocols

Community sources describe the following combinations; no published trials evaluate them.

Community-Reported Stack: 5-Amino-1MQ + MOTS-c

Compound Route Community-reported dose Timing Reported rationale
5-Amino-1MQ Oral 100 mg/day AM NNMT inhibition, NAD+ restoration
MOTS-c SC injection 5-10 mg/week AM, 2-3x/week AMPK activation, insulin sensitivity

Community-Reported Stack: 5-Amino-1MQ + Tesofensine

Compound Route Community-reported dose Timing Reported rationale
5-Amino-1MQ Oral 100 mg/day AM Metabolic pathway (NNMT/NAD+)
Tesofensine Oral 0.5 mg/day AM Appetite suppression (DA/NE/5-HT)

Community sources describe the pairing as combining a proposed metabolic mechanism with an appetite-suppressant one; no combined-use human data exist. Community sources note that combining multiple metabolic compounds can amplify stimulant-like effects.

Side Effects & Safety

Community reports describe:

  • Mild GI discomfort — most common, usually transient in the first week
  • Slight stimulant effect — increased energy/alertness, especially early on
  • Headaches — occasional, typically mild and dose-related
  • Mild insomnia — community reports link it to later-in-day dosing
  • No human clinical safety data — all safety information from preclinical studies and community reports
  • No liver toxicity reported in the cited mouse studies
  • Unknown drug interactions — theoretically could interact with NAD+-dependent pathways

Frequently Asked Questions

What doses do community sources and preclinical research report for 5-Amino-1MQ?
Community-reported starting doses are 50 mg/day for 1-2 weeks, escalating to 100-150 mg/day. Most reported protocols settle at 100 mg for maintenance. Reported cycle lengths are 8-12 weeks on, 4-8 weeks off.
Which routes do community sources and vendors describe for 5-Amino-1MQ?
Both are sold. Oral capsules are the better-documented route — Caco-2 assays showed excellent membrane permeability with no detectable efflux, so the compound does not depend on injection the way most peptides do. Vendors also sell 10mg, 20mg and 50mg vials for subcutaneous use, and community protocols exist for it. No human trial has established a dose for either route.
Is there a 5-Amino-1MQ injection dosage per day?
The community protocol reports 1 mg subcutaneously in the morning (20 units from a 10 mg vial reconstituted with 2 mL), 5 days on and 2 days off, for 8 weeks on and 8 weeks off. Higher figures also circulate: 2.5 mg once daily for the first day or two, then 5 mg once daily, or 2.5 mg twice daily as a split. These are reported practice, not trial data. All of them are far below the oral figures (50-150 mg/day) and the two are not interchangeable, because no human study has established a conversion between the routes. The 20 mg/kg figure that circulates is from mouse studies and does not scale to humans.
What cycle lengths do community sources report for 5-Amino-1MQ?
Community protocols report 8-12 weeks on, followed by 4-8 weeks off; sources commonly cite the absence of long-term human safety data as the rationale for cycling.
Does 5-Amino-1MQ suppress appetite?
In diet-induced-obese mice, treatment reduced body weight without changing food intake, so the proposed mechanism is NNMT inhibition affecting adipose-tissue energy expenditure and NAD+ availability rather than appetite suppression. No human data exist.
What stacking protocols are documented for 5-Amino-1MQ?
Community sources document stacking with MOTS-c for mitochondrial support and tesofensine for complementary appetite suppression. Community sources describe introducing each compound individually before combining.
What are the side effects of 5-Amino-1MQ?
Community reports include mild GI discomfort, occasional headaches, and slight stimulant-like effects. No human clinical trials exist, so long-term safety is unknown.

References

Citation Topic PMID
Neelakantan et al., Biochem Pharmacol (2018) 5-Amino-1MQ reverses diet-induced obesity, oral bioavailability 29155147
Kraus et al., Nature (2014) NNMT knockdown protects against diet-induced obesity 24717514
Neelakantan et al., Sci Rep (2022) NNMT inhibition + reduced calorie diet, microbiome effects 35013352
Liu et al., BioMed Res Int (2021) NNMT roles in obesity and type 2 diabetes review 34368359

For educational and research purposes only. This is not medical advice. 5-Amino-1MQ has no human clinical trials; all dosing is community-derived.